Structural and biochemical studies are proposed to examine protein- protein and protein-lipid interactions involved in viral budding and viral maturation. The focus is on the plus-strand RNA viruses, which either cause human disease or are closely related to viruses which cause human disease. The budding process and nucleocapsid stabilization will be investigated by NMR and other methods for alphavirus, hepatitis C virus, rubella virus, and yellow fever virus, the most simple enveloped viruses. Structural features important for capsid stabilization and maturation will be investigated by NMR for Rous sarcoma virus (RSV), a structurally more complex retrovirus. Specific objectives are to understand the importance of the capsid-nucleocapsid region of the RSV Gag protein by determining 3-dimensional solution structures of various RSV protein constructs, and characterizing interdomain interactions for the C-terminal domain of capsid (CA) protein, the nucleocapsid (NC) protein, and the capsid-nucleocapsid core particles and the transmembrane E2- glycoprotein has been proposed and will be tested by biochemical and NMR experiments. Further studies to investigate nucleocapsid stability are also proposed for yellow fever virus (YFV), hepatitis C virus (HCV), and rubella virus (RUBV) using NMR methods combined with mutagenesis results. Results from the studies proposed in this project, coupled with results from molecular genetics and crystallography proposed elsewhere in the Program Project, will enhance our understanding of the structural and physical basis underlying viral assembly.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
FlaviviridaeRNA virusRubivirusbioimaging /biomedical imagingcapsidhepatitis C virusnuclear magnetic resonance spectroscopynucleocapsidprotein protein interactionprotein structure functionstructural biologyvirus assemblyvirus proteinvirus replication
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
072051394
UEI
YRXVL4JYCEF5
Project Start Date
01-September-2000
Project End Date
31-August-2001
Budget Start Date
Budget End Date
Project Funding Information for 2000
Total Funding
$166,157
Direct Costs
$166,157
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2000
National Institute of Allergy and Infectious Diseases
$166,157
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI045976-02 0004
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI045976-02 0004
Patents
No Patents information available for 5P01AI045976-02 0004
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI045976-02 0004
Clinical Studies
No Clinical Studies information available for 5P01AI045976-02 0004
News and More
Related News Releases
No news release information available for 5P01AI045976-02 0004
History
No Historical information available for 5P01AI045976-02 0004
Similar Projects
No Similar Projects information available for 5P01AI045976-02 0004